Two international companies begin due diligence on Redwood Pharma's product RP501 ahead of potential commercial agreements

Virtual data rooms are online platforms that contain confidential information about assets of commercial interest. Access to the data room is provided on a strictly confidential basis to potential partners for their evaluation of sensitive information including details of completed clinical studies and market research, intellectual property rights as well as discussions with regulatory authorities. Data rooms are crucial in an evaluation (due diligence) which in turn can lead to the signing of a commercial agreement.

"For some time now, we have had several parallel discussions with potential commercial partners who have shown great interest in the unique and revolutionary medical technology product RP501, and it is gratifying that two of these stakeholders have now chosen to sign confidentiality agreements. It gives them the opportunity to move forward in the process and carry out a thorough due diligence of the project," says Martin Vidaeus, CEO of Redwood Pharma.

RP501 is being developed to be an effective and user-friendly over-the-counter thermogel for the temporary relief of dry eye, a condition that affects more than 300 million people worldwide. The results of a clinical study show that RP501 is safe, provides a significant therapeutic effect already at a dosage of 1-2 drops per day and is convenient to use - characteristics that consumers consider the most important parameters for a dry eye product.

For reasons of confidentiality, Redwood Pharma is prevented from disclosing the names of the companies that have now begun the due diligence process of RP501. The company is in an early phase of a business process with the interested parties and that there are no guarantees that they will lead to final agreements.